RekrutujeFaza III
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Miasta: Białystok, Bydgoszcz, Elbląg, Grudzadz i 11 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza II
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Miasta: Bydgoszcz, Chorzów, Kraków, Lublin i 12 innych miastWiek: od 18 latSponsor: Eli Lilly & Co.
RekrutujeFaza II
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Bytom, Kalisz, Katowice i 17 innych miastWiek: od 18 latSponsor: Abivax
RekrutujeFaza III
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Miasta: Bydgoszcz, Chorzów, Jelenia Góra, Kraków i 13 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza II
Assessment of the safety and effectiveness of vedolizumab induction therapy compared to standard infliximab therapy in pediatric patients with ulcerative colitis "VEDI-UC”
Miasta: Białystok, Gdańsk, Katowice, Lublin i 6 innych miastWiek: do 17.99 latSponsor: Instytut Pomnik Centrum Zdrowia Dziecka
RekrutujeFaza IV
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Miasta: Katowice, Opole, Poznań, Rzeszów i 5 innych miastWiek: od 18 latSponsor: Alimentiv Inc.
RekrutujeFaza II
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Lublin, Poznań, Rzeszów i 8 innych miastWiek: od 18 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza II
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Bytom, Częstochowa, Elbląg i 11 innych miastWiek: od 18 latSponsor: Morphic Therapeutic Inc.
RekrutujeFaza III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Miasta: Rzeszów, Warszawa, WrocławWiek: do 17.99 latSponsor: Eli Lilly & Co.
RekrutujeFaza III
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Miasta: Gdańsk, Katowice, Kraków, Rzeszów i 4 inne miastaWiek: do 17.99 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza II
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Miasta: Katowice, Kraków, Szczecin, Warszawa i 2 inne miastaWiek: do 17.99 latSponsor: Arena Pharmaceuticals Inc.
RekrutujeFaza II/III
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Miasta: Gdańsk, Kraków, Rzeszów, Szczecin i 3 inne miastaWiek: do 17.99 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Miasta: Rzeszów, Szczecin, Warszawa, WrocławWiek: 2-19 latSponsor: Eli Lilly and Company
RekrutujeFaza III
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Miasta: Gdańsk, Katowice, Kraków, Rzeszów i 4 inne miastaWiek: do 17.99 latSponsor: Takeda Development Center Americas Inc.
Rekrutacja wkrótceFaza I
LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
Miasta: Rzeszów, Warszawa, WrocławWiek: 18-64 latSponsor: Medytox Inc.